{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:06:57Z","timestamp":1789060017281,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117013","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:03:37Z","timestamp":1787760217000},"page":"117013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial"],"prefix":"10.1016","volume":"246","author":[{"given":"Maria E.","family":"Cabanillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naifa L.","family":"Busaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-9739","authenticated-orcid":false,"given":"Mark","family":"Zafereo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-355X","authenticated-orcid":false,"given":"Priyanka C.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1528-9885","authenticated-orcid":false,"given":"Sarah","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ferrarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-2646","authenticated-orcid":false,"given":"Suyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary B.","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spiotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4354-2841","authenticated-orcid":false,"given":"Anastasios","family":"Maniakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4418-3705","authenticated-orcid":false,"given":"Maria","family":"Gule-Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-7332","authenticated-orcid":false,"given":"Michelle D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Mohsen","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E.","family":"Banuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-030X","authenticated-orcid":false,"given":"Mimi I.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2932-5584","authenticated-orcid":false,"given":"Matthew","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Dadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2026.117013_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00504","article-title":"Impact of somatic mutations on survival outcomes in patients with anaplastic thyroid carcinoma","author":"Wang","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.117013_bib2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117013_bib3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint Inhibition in Addition to Dabrafenib\/Trametinib for BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.ejca.2026.117013_bib4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/thy.2022.0504","article-title":"Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF(V600E) Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study","volume":"33","author":"Zhao","year":"2023","journal-title":"Thyroid"},{"key":"10.1016\/j.ejca.2026.117013_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ejca.2026.117013_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.ejca.2026.117013_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1089\/thy.2025.0194","article-title":"Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer","volume":"35","author":"Cabanillas","year":"2025","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ejca.2026.117013_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1089\/thy.2025.0044","article-title":"Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure","volume":"35","author":"Cabanillas","year":"2025","journal-title":"Thyroid"},{"issue":"21","key":"10.1016\/j.ejca.2026.117013_bib9","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.117013_bib10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/thy.2012.0103","article-title":"Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid","volume":"23","author":"Savvides","year":"2013","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ejca.2026.117013_bib11","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2012-1520","article-title":"A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer","volume":"97","author":"Bible","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2026.117013_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama","year":"2022","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1016\/j.ejca.2026.117013_bib13","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 Blockade in Anaplastic Thyroid Carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.117013_bib14","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/ijc.32041","article-title":"Anti-PD-1\/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer","volume":"144","author":"Gunda","year":"2019","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2026.117013_bib15","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ejca.2026.117013_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/10507256251409138","article-title":"Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma","volume":"36","author":"Hamidi","year":"2026","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ejca.2026.117013_bib17","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-25-0301","article-title":"Real-world efficacy of lenvatinib\/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers","volume":"15","author":"Talpacci","year":"2026","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ejca.2026.117013_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1726","article-title":"Phase II ATLEP trial: Final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma","volume":"33","author":"Dierks","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117013_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1191\/1740774505cn121oa","article-title":"Monitoring event times in early phase clinical trials: some practical issues","volume":"2","author":"Thall","year":"2005","journal-title":"Clin Trials"},{"key":"10.1016\/j.ejca.2026.117013_bib20","article-title":"Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues","author":"Hamidi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejca.2026.117013_bib21","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0144","article-title":"Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer","volume":"13","author":"Tan","year":"2024","journal-title":"Eur Thyroid J"},{"issue":"5","key":"10.1016\/j.ejca.2026.117013_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70710","article-title":"Evaluation of Treatment Response and Survival Outcomes in Anaplastic Thyroid Cancer Patients Following Surgery With and Without Other Treatment Modalities: A Systematic Review","volume":"8","author":"Negahban","year":"2025","journal-title":"Health Sci Rep"},{"issue":"1","key":"10.1016\/j.ejca.2026.117013_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1272\/jnms.2018_85-3","article-title":"Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan","volume":"85","author":"Sugitani","year":"2018","journal-title":"J Nippon Med Sch"},{"issue":"12","key":"10.1016\/j.ejca.2026.117013_bib24","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1","article-title":"Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival","volume":"91","author":"Haigh","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.117013_bib25","article-title":"Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC): A multicenter phase 2 trial","volume":"42","author":"Zafereo","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117013_bib26","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.21873\/anticanres.13537","article-title":"Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer","volume":"39","author":"Staub","year":"2019","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2026.117013_bib27","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1089\/thy.2012.0598","article-title":"Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer","volume":"24","author":"Blevins","year":"2014","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ejca.2026.117013_bib28","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600794X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600794X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:10:09Z","timestamp":1789056609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600794X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S095980492600794X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117013"}}